MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel

Rachel Grossman, Peter Burger, Ethan Soudry, Betty Tyler, Kaisorn L. Chaichana, Jon Weingart, Alessandro Olivi, Gary L. Gallia, David Sidransky, Alfredo Quiñones-Hinojosa, Xiaobu Ye, Henry Brem

Research output: Contribution to journalArticle

Abstract

We examined the relationship between the O6-methylguanine-methyltransferase (MGMT) methylation status and clinical outcomes in newly diagnosed glioblastoma multiforme (GBM) patients who were treated with Gliadel wafers (Eisai, Tokyo, Japan). MGMT promoter methylation has been associated with increased survival among patients with GBM who are treated with various alkylating agents. MGMT promoter methylation, in DNA from 122 of 160 newly diagnosed GBM patients treated with Gliadel, was determined by a quantitative methylation-specific polymerase chain reaction, and was correlated with overall survival (OS) and recurrence-free survival (RFS). The MGMT promoter was methylated in 40 (32.7%) of 122 patients. The median OS was 13.5 months (95% confidence interval [CI] 11.0-14.5) and RFS was 9.4 months (95% CI 7.8-10.2). After adjusting for age, Karnofsky performance score, extent of resection, temozolomide (TMZ) and radiation therapy (RT), the newly diagnosed GBM patients with MGMT methylation had a 15% reduced mortality risk, compared to patients with unmethylated MGMT (hazard ratio 0.85; 95% CI 0.56-1.31; p = 0.46). The patients aged over 70 years with MGMT methylation had a significantly longer median OS of 13.5 months, compared to 7.6 months in patients with unmethylated MGMT (p = 0.027). A significant difference was also found in older patients, with a median RFS of 13.1 versus 7.6 months for methylated and unmethylated MGMT groups, respectively (p = 0.01). Methylation of the MGMT promoter in newly diagnosed GBM patients treated with Gliadel, RT and TMZ, was associated with significantly improved OS compared to the unmethylated population. In elderly patients, methylation of the MGMT promoter was associated with significantly better OS and RFS.

Original languageEnglish (US)
Pages (from-to)1938-1942
Number of pages5
JournalJournal of Clinical Neuroscience
Volume22
Issue number12
DOIs
StatePublished - Dec 2015

    Fingerprint

Keywords

  • Gliadel
  • Glioblastoma multiforme
  • MGMT
  • Methylation
  • Outcome
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this